{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Overall Response Rate in Intent to Treat population"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Overall Response Rate in TFH-phenotype lymphomas"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Estimate the response rate of the combination therapy in refractory or recurrent PTCL.","groups":[{"description":"Pembrolizumab 200mg IV D1 + Romidepsin 14mg/m² IV D1, D8 q21d","id":"OG000","title":"Cohort 1"}],"paramType":"NUMBER","populationDescription":"This is a phase Ib/II study, it was more safety run-in for Ib followed by phase II. This is a single arm trial. We have shown the calculation and how the 47% uses 38 as denominator for responders and the denominator for TfH/AITL to calculate the number. We are calculating ORR for the whole and the subset so the denominators will have to be different and hence the TfH subtype will have higher ORR because of higher number of patients with CR when comparing them within the TfH cohort.","reportingStatus":"POSTED","timeFrame":"7 years and 4 months","title":"Evaluate the Safety of Pembrolizumab in Combination With Romidepsin.","type":"PRIMARY","unitOfMeasure":"percentage of participants"}